Compare GSK plc (GSK) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Msci Inc — how do they compare? GSK plc trades at $52.54 (market cap $101.34B), while Msci Inc trades at $630.49 (market cap $45.26B). The key difference: GSK plc is far larger — about 2.2× Msci Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MSCI | |
|---|---|---|
Market Cap | $101.34B | $45.26B |
Sector | Health | Financials |
52-Week High | $61.18 | $643.83 |
52-Week Low | $36.20 | $511.84 |
Enterprise Value | $121.95B | $51.43B |
Dividend Yield | 3.49% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
MSCI trades at $626.59, up 2.48% today, with strong technical momentum as the stock approaches resistance at $628. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.55 versus $4.44, maintaining a three-quarter earnings beat streak. Recent strategic partnerships with UBS and the acquisition of First Street highlight growth initiatives in private markets and climate risk analytics. Valuation metrics show a P/E of 35.51 and P/S of 14.5, reflecting premium pricing for consistent performance.
The outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and a price target of $718.14 offering 15% upside potential. Key risks include high debt levels at $4.51 billion and sensitivity to financial market conditions. The upcoming Q2 2026 earnings report on July 21, 2026, will be critical for validating growth trajectory amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
